Help
Subscribe


All of GastroHep is now free access! - Click here to register Read For FREE - Our full range of review articles
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Guido Tytgat Profile of Pete Peterson Profile of Peter Cotton Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Radiofrequency ablation and endoscopic mucosal resection for dysplastic Barrett's esophagus

The latest issue of Gastroenterology investigates the use of radiofrequency ablation and endoscopic mucosal resection for dysplastic Barrett's esophagus and early esophageal adenocarcinoma.

News image

Patients with Barrett's esophagus and high-grade dysplasia or early neoplasia increasingly receive endoscopic mucosal resection and radiofrequency ablation therapy.

Dr Rehan Haidry and colleagues from the United Kingdom analyzed data from a UK registry that follows the outcomes of patients with Barrett's Esophagus who have undergone resection and radiofrequency ablation for neoplasia.

The research team reported that they collected data on 335 patients with Barrett's esophagus and neoplasia, treated at 19 centers in the United Kingdom from 2008 through 2012.

Mean length of Barrett's esophagus segments was 5.8 cm.

Patients' nodules were removed by endoscopic mucosal resection, and the patients then underwent resection and radiofrequency ablation every 3 months until all areas of Barrett's esophagus were ablated or cancer developed.

The research team collected biopsies for 12 months after the first resection and radiofrequency ablation; clearance of high-grade dysplasia, dysplasia, and Barrett's esophagus were assessed

Symptomatic strictures developed in 9% of patients
Gastroenterology

High-grade dysplasia was cleared from 86% of patients, all dysplasia from 81%, and Barrett's esophagus from 62% at the 12-month time point, after a mean of 2.5 resection and radiofrequency ablation procedures.

The doctors noted that complete reversal dysplasia was 15% less likely for every 1-cm increment in Barrett's esophagus length.

Endoscopic mucosal resection before resection and radiofrequency ablation did not provide any benefit.

Invasive cancer developed in 10 patients by the 12-month time point and disease had progressed in 17 patients after a median follow-up time of 19 months.

The doctors found that symptomatic strictures developed in 9% of patients and were treated by endoscopic dilatation.

The team observed that 19 months after therapy began, 94% of patients remained clear of dysplasia.

Dr Haidry's team commented, "We analyzed data from a large series of patients in the United Kingdom who underwent resection and radiofrequency ablation for Barrett's esophagus-related neoplasia and found that by 12 months after treatment, dysplasia was cleared from 81%. "

"Shorter segments of Barrett's esophagus respond better to resection and radiofrequency ablation."

Gastroenterol 2013: 145(1) 87-95
15 July 2013

Go to top of page Email this page Email this page to a colleague

 06 March 2015

Advanced search
 06 March 2015 
Second anti-TNF in IBD
 06 March 2015 
Efficacy of Hep E vaccine
 06 March 2015 
Steroid therapy for eosinophilic esophagitis
 05 March 2015 
EPHXI polymorphism and esophageal cancer risk
 05 March 2015 
Infliximab and immunosuppressant therapy in ulcerative colitis
 05 March 2015 
Neuroendocrine carcinoma of the colon and rectum
 04 March 2015 
Multidisciplinary management of rectal cancer
 04 March 2015 
Management of IBD
 04 March 2015 
Progression of Barrett's
 03 March 2015 
EPHX1 polymorphism and esophageal cancer risk
 03 March 2015 
Risk of anastomotic leak after colectomy
 03 March 2015 
GI bleeding in chronic kidney disease patients on aspirin
 02 March 2015 
Genes and early diagnosis of IBD
 02 March 2015 
Assessment of GERD
 02 March 2015 
Liver disease in patients awaiting liver transplant
 27 February 2015 
Obesity and weight-loss therapy
 27 February 2015 
MRE performance in staging liver fibrosis
 27 February 2015 
Bleeding in diverticulosis
 26 February 2015 
Familial colorectal cancer risk and primary cancer
 26 February 2015 
Herbal products and the liver
 26 February 2015 
Questionnaires for GERD
 25 February 2015 
Exercise and NAFLD
 25 February 2015 
IBD in Korea
 25 February 2015 
Immunosuppressive therapy and T. whipplei
 24 February 2015 
Clinical trials in pediatric IBD
 24 February 2015 
Reducing health care costs in IBD
 24 February 2015 
GI bleeding after anticoagulation interruption
 23 February 2015 
Visceral abdominal obesity and IBS
 23 February 2015 
Crohn's outcomes with infliximab
 23 February 2015 
Intestinal microbiota and celiac disease
 20 February 2015 
H. pylori eradication
 20 February 2015 
Antiviral treatment and Hep C outcomes
 20 February 2015 
C. diff testing in IBD
 19 February 2015 
Peptic ulcer bleeding mortality in liver disease
 19 February 2015 
Intestinal microbiota in IBS
 19 February 2015 
Fecal microbial transplant in active Crohn's disease
 18 February 2015 
Genetic testing and GI cancers
 18 February 2015 
Placebo analgesia in functional abdominal pain
 18 February 2015 
Successful Hep C virus therapy
 17 February 2015 
Quality measures and colonoscopist selection
 17 February 2015 
Global incidence of esophageal cancer
 17 February 2015 
Anti-viral treatment and survival in Hep C
 16 February 2015 
Saliva for the diagnosis of GERD
 16 February 2015 
H pylori eradication therapy
 16 February 2015 
Medical marijuana for digestive disorders
 13 February 2015 
Beta-blockers in cirrhosis
 13 February 2015 
Liver disease and peptic ulcer bleeding
 13 February 2015 
Prevalence of microscopic colitis
 12 February 2015 
Liver disease in chronic Hep C
 12 February 2015 
Patient-reported outcomes in Hep C
 12 February 2015 
Patientsí colonoscopist selection
 11 February 2015 
Hepatic decompensation in Hep C cirrhosis
 11 February 2015 
Guidelines for the diagnosis of hepatocellular carcinoma
 11 February 2015 
NAFLD and CVD
 10 February 2015 
Percutaneous endoscopic gastrostomy
 10 February 2015 
Factors that influence hepatic steatosis
 10 February 2015 
Gene variants and Crohn's susceptibility
 09 February 2015 
Factors that influence gallstone surgery
 09 February 2015 
Factors associated with increased mortality in cirrhosis
 09 February 2015 
Use of immunomodulators in IBD

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2015 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us